SCHEMBL2307975

SCHEMBL2307975

Cc1nc2cc(CC(N)C(=O)O)ccc2o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRA P18433 1/20 0.58
PTPRB P23467 1/20 0.58
PKM P14618 3/20 0.56
HIF1A Q16665 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
BRCA1 P38398 1/20 0.53
RAB9A P51151 5/20 0.49
SLC7A5 Q01650 7/20 0.49
KDM4E B2RXH2 3/20 0.49
PTGS1 P23219 2/20 0.49
USP2 O75604 1/20 0.49
EGFR P00533 1/20 0.49
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
ALOX15 P16050 1/20 0.49
HTR2A P28223 1/20 0.49
PTGS2 P35354 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068034 0.81 PTPRA (0.61) PTPRAPTPRBPKMHIF1AALDH1A1
SCHEMBL1068031 0.81 PTPRA (0.61) PTPRAPTPRBPKMHIF1AALDH1A1
SCHEMBL3807350 0.79 GAA (0.69) ALDH1A1RAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL8201185 0.78 L3MBTL1 (0.49) ALDH1A1RAB9AKDM4EHSD17B10NPC1
SCHEMBL7420912 0.77 ITGB1 (0.68) PTPRAPTPRBPKMHIF1AALDH1A1
SCHEMBL7420913 0.77 ITGB1 (0.68) PTPRAPTPRBPKMHIF1AALDH1A1
SCHEMBL17385281 0.76 GAA (0.51) ALDH1A1RAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL11100833 0.76 GAA (0.45) PTPRAPTPRBHIF1AALDH1A1CYP1A2
SCHEMBL16971289 0.75 PTPRA (0.55) PTPRAPTPRBPKMHIF1AALDH1A1
SCHEMBL16971288 0.75 PTPRA (0.55) PTPRAPTPRBPKMHIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288549-B2 Glycine B antagonist MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-16 US disclosed
US-20110190342-A1 GLYCINE B ANTAGONIST HENRICH MARKUS 2011-08-04 US disclosed
EP-2350014-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2011-08-03 EP disclosed
WO-2010037533-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA (DE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190342-A1 GLYCINE B ANTAGONIST GRIN2B, GLRB, GRIN2A PTPRA 4049/4885PTPRB 2751/4885PKM 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.